|
gptkbp:instanceOf
|
gptkb:drug
proton pump inhibitor
|
|
gptkbp:approvedBy
|
1992
|
|
gptkbp:ATCCode
|
A02BC03
|
|
gptkbp:bioavailability
|
80-90%
|
|
gptkbp:brand
|
Prevacid
Takepron
Zoton
Inhibitol
Lanzor
|
|
gptkbp:CASNumber
|
103577-45-3
|
|
gptkbp:contraindication
|
hypersensitivity to lansoprazole
|
|
gptkbp:discoveredBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:eliminationHalfLife
|
1.0-1.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
orally disintegrating tablet
delayed-release capsule
granules for oral suspension
|
|
gptkbp:hasMolecularFormula
|
C16H14F3N3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lansoprazole
|
|
gptkbp:KEGGID
|
D00318
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:liverEnzymeInteraction
|
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:mechanismOfAction
|
inhibits H+/K+ ATPase in gastric parietal cells
|
|
gptkbp:MedlinePlusID
|
a697056
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
369.36 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
B (US)
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:PubChem_CID
|
CHEMBL685
3883
DB00448
|
|
gptkbp:riskFactor
|
may cause low magnesium with long-term use
may increase risk of bone fracture with long-term use
may increase risk of Clostridium difficile infection
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
constipation
headache
rash
|
|
gptkbp:UNII
|
0K5C5YSJQZ
|
|
gptkbp:usedFor
|
gptkb:Zollinger-Ellison_syndrome
gptkb:erosive_esophagitis
gptkb:gastroesophageal_reflux_disease
gptkb:peptic_ulcer_disease
helicobacter pylori eradication
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|